B

BioCardia

BCDA

2.96000
USD
-0.05
(-1.66%)
مغلق
حجم التداول
354
الربح لكل سهم
0
العائد الربحي
0
P/E
-0
حجم السوق
8,159,348
الأخبار المقالات

العنوان: BioCardia Inc.

القطاع: Healthcare
الصناعة: Biotechnology
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP(R) autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).